当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Clinical activity of arsenic trioxide for the treatment of multiple myeloma.

Clinical activity of arsenic trioxide for the treatment of multiple myeloma.

Abstract：

:Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. In the early 1990s, reports from China described impressive results with arsenic trioxide in patients with de novo, relapsed, and refractory acute promyelocytic leukemia (APL). Other investigators subsequently confirmed these results leading to approval of its use for relapsed or refractory APL in the United States. Investigations of this agent have demonstrated that its efficacy in APL and preclinical tumor models is dependent upon a number of mechanisms, including induction of apoptosis, effects on cellular differentiation, cell cycling, and tumor angiogenesis. Subsequent preclinical studies showed significant activity of arsenic trioxide in multiple myeloma (MM). Based on this, in a phase II trial, we have evaluated the activity of arsenic trioxide in 14 patients with relapsed MM, refractory to conventional salvage therapy. With the dose and schedule used, treatment with arsenic trioxide produced responses in three patients and prolonged stable disease in a fourth patient, with the longest response lasting 6 weeks. Although treatment was reasonably well tolerated, in these patients with extensive prior therapy, 11 developed cytopenia, five associated with infectious complications and three developed deep vein thromboses. The results of this small trial support further investigation of this novel drug for the treatment of patients with relapsed or refractory MM.

journal_name

Leukemia

journal_title

Leukemia

authors

Munshi NC,Tricot G,Desikan R,Badros A,Zangari M,Toor A,Morris C,Anaissie E,Barlogie B

doi

10.1038/sj.leu.2402599

subject

Has Abstract

pub_date

2002-09-01 00:00:00

pages

1835-7

issue

9

eissn

0887-6924

issn

1476-5551

journal_volume

16

pub_type

临床试验,杂志文章

相关文献

LEUKEMIA文献大全
  • Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

    abstract：:Lovastatin is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the major regulatory enzyme of the mevalonate pathway. We have previously reported that lovastatin induces a significant apoptotic response in human acute myeloid leukemia (AML) cells. To identify the critical biochemic...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402196

    authors： Xia Z,Tan MM,Wong WW,Dimitroulakos J,Minden MD,Penn LZ

    更新日期：2001-09-01 00:00:00

  • The molecular characterization and clinical management of multiple myeloma in the post-genome era.

    abstract：:Cancer-causing mutations disrupt coordinated, precise programs of gene expression that govern cell growth and differentiation. Microarray-based gene-expression profiling (GEP) is a powerful tool to globally analyze these changes to study cancer biology and clinical behavior. Despite overwhelming genomic chaos in multi...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.160

    authors： Zhou Y,Barlogie B,Shaughnessy JD Jr

    更新日期：2009-11-01 00:00:00

  • Growth and differentiation of a murine interleukin-3-producing myelomonocytic leukemia cell line in a protein-free chemically defined medium.

    abstract：:We established the continuous growth of WEHI-3B D+ cells in protein-free chemically defined F-12 medium by stepwise decreases in the concentration of fetal calf serum. This cell line, designated as WEHI-3B-Y1, has now been propagated in protein-free F-12 medium for 3 years. The population-doubling time of the cells in...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Kajigaya Y,Ikuta K,Sasaki H,Matsuyama S

    更新日期：1990-10-01 00:00:00

  • Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.

    abstract：:Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B-cell malignancies,...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-020-01072-6

    authors： Wen T,Wang J,Shi Y,Qian H,Liu P

    更新日期：2020-10-29 00:00:00

  • Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells.

    abstract：:Cellular stressors induce various outcomes including inhibition of cell proliferation and cell death. Sodium salicylate (SA), a plant stress hormone, can suppress the proliferation or cause apoptosis in certain mammalian cancer cells. Plant stress hormones are activators of cellular responses, including cell death, to...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402419

    authors： Fingrut O,Flescher E

    更新日期：2002-04-01 00:00:00

  • S100A6 is a critical regulator of hematopoietic stem cells.

    abstract：:The fate options of hematopoietic stem cells (HSCs) include self-renewal, differentiation, migration, and apoptosis. HSCs self-renewal divisions in stem cells are required for rapid regeneration during tissue damage and stress, but how precisely intracellular calcium signals are regulated to maintain fate options in n...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0901-2

    authors： Grahn THM,Niroula A,Végvári Á,Oburoglu L,Pertesi M,Warsi S,Safi F,Miharada N,Garcia SC,Siva K,Liu Y,Rörby E,Nilsson B,Zubarev RA,Karlsson S

    更新日期：2020-12-01 00:00:00

  • Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

    abstract：:We analyzed mRNA expression of the flt3 gene in 30 patients with acute myeloid leukemia (AML) and 50 with acute lymphoblastic leukemia (ALL). Using reverse transcriptase-polymerase chain reaction (RT-PCR), expression of flt3 was observed in 61 patients; 22 (73%) with AML and 39 (78%) with ALL. Among these, five patien...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Nakao M,Yokota S,Iwai T,Kaneko H,Horiike S,Kashima K,Sonoda Y,Fujimoto T,Misawa S

    更新日期：1996-12-01 00:00:00

  • Interferon alpha in the therapy of multiple myeloma.

    abstract：:Response rates of 20% were achieved when interferon alpha (IFN) was applied as single agent treatment for multiple myeloma. A synergistic activity was observed when IFN was combined with chemotherapeutic agents in vitro and in vivo. These observations led to a series of randomized trials comparing chemotherapy alone w...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Gisslinger H

    更新日期：1997-12-01 00:00:00

  • Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

    abstract：:In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2014.60

    authors： Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

    更新日期：2014-08-01 00:00:00

  • Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells.

    abstract：:Transcriptional regulation of the HOXA genes is thought to involve CTCF-mediated chromatin loops and the opposing actions of the COMPASS and Polycomb epigenetic complexes. We investigated the role of these mechanisms at the HOXA cluster in AML cells with the common NPM1c mutation, which express both HOXA and HOXB gene...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-0856-3

    authors： Ghasemi R,Struthers H,Wilson ER,Spencer DH

    更新日期：2020-05-12 00:00:00

  • Imatinib sensitizes CLL lymphocytes to chlorambucil.

    abstract：:The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, respectively, to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403247

    authors： Aloyz R,Grzywacz K,Xu ZY,Loignon M,Alaoui-Jamali MA,Panasci L

    更新日期：2004-03-01 00:00:00

  • Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesis.

    abstract：:CAMAL (common antigen in myelogenous acute leukemia) is an antigenic preparation isolated in this laboratory from the bone marrow or peripheral blood cells of persons with myeloid leukemias and shown in an immunoperoxidase slide test to be diagnostic of these leukemias. CAMAL has been shown to be inhibitory to myelopo...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Leitch HA,Buskard N,Levy JG

    更新日期：1993-09-01 00:00:00

  • Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

    abstract：:Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Crucial questions in clinical decision-making include the definition of optimal timing of the procedure and the ben...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.88

    authors： Della Porta MG,Jackson CH,Alessandrino EP,Rossi M,Bacigalupo A,van Lint MT,Bernardi M,Allione B,Bosi A,Guidi S,Santini V,Malcovati L,Ubezio M,Milanesi C,Todisco E,Voso MT,Musto P,Onida F,Iori AP,Cerretti R,Grillo

    更新日期：2017-11-01 00:00:00

  • Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.

    abstract：:Lymphokine-activated killer (LAK) cell activity generated from peripheral blood was tested in 6 patients with typical hairy cell leukemia, 3 not on treatment with alpha-interferon (alpha-IFN) and 3 receiving therapy. In all cases, substantial killing of the LAK-sensitive target Daudi was observed, but hairy cells, whe...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Griffiths SD,Cawley JC

    更新日期：1988-06-01 00:00:00

  • Harmonization of molecular monitoring of CML therapy in Europe.

    abstract：:The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at levels below the landmark of complete cytogenetic remission. Quantification of BCR-ABL transcripts has proven to be the most sensitive method available, and has ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.168

    authors： Müller MC,Cross NC,Erben P,Schenk T,Hanfstein B,Ernst T,Hehlmann R,Branford S,Saglio G,Hochhaus A

    更新日期：2009-11-01 00:00:00

  • Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

    abstract：:Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to therapy in chronic myeloid leukaemia (CML). We wanted to determine in what circumstances additional clinically relevant information was provided by simultane...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404139

    authors： Ross DM,Branford S,Moore S,Hughes TP

    更新日期：2006-04-01 00:00:00

  • KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.

    abstract：:Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine residues of histones and play a central role in transcriptional regulation in diverse biological processes. Dysregulation of HAT activity can lead to human diseases including developmental disorders and cancer. Through...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-1001-z

    authors： Au YZ,Gu M,De Braekeleer E,Gozdecka M,Aspris D,Tarumoto Y,Cooper J,Yu J,Ong SH,Chen X,Tzelepis K,Huntly BJP,Vassiliou G,Yusa K

    更新日期：2020-08-06 00:00:00

  • CLL family 'Pedigree 14' revisited: 1947-2004.

    abstract：:The notion that inherited predisposition contributes to the development of haematological malignancies is generally thought of as being a relatively new idea. However, Videbaek made a clear enunciation of such a hypothesis in 1947, from a study of tumour incidence in relatives of patients with different leukaemias. To...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403727

    authors： Jønsson V,Houlston RS,Catovsky D,Yuille MR,Hilden J,Olsen JH,Fajber M,Brandt B,Sellick G,Allinson R,Wiik A

    更新日期：2005-06-01 00:00:00

  • Basic fibroblast growth factor and hematopoiesis.

    abstract：:Basic fibroblast growth factor (bFGF or FGF-2) is an angiogenic and pleiotropic factor involved in the proliferation and differentiation of numerous cell types. It is expressed mostly in tissues of mesoderm and neuroectoderm origin, and plays an important role in the mesoderm induction, together with transforming grow...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Allouche M

    更新日期：1995-06-01 00:00:00

  • Prevention of T-cell lymphoma in AKR/J mice.

    abstract：:Injection of a dual tropic virus (DTV) isolated from a T cell lymphoma AKR/J mice into the thymus of 14 day old AKR/J puppies accelerates lymphoma development; 90-100% of the injected mice develop the disease within 120 days. In contrast a cell free centrifuge CFC-666 prepared B cell lymphoma of AKR/J origin injected ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Peled A,Haran-Ghera N

    更新日期：1988-12-01 00:00:00

  • Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing.

    abstract：:Depending on disease stage follicular lymphoma (FL) lack the t(14;18) in ~15-~50% of cases. Nevertheless, most of these cases express BCL2. To elucidate mechanisms triggering BCL2 expression and promoting pathogenesis in t(14;18)-negative FL, exonic single-nucleotide variant (SNV) profiles of 28 t(14;18)-positive and ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.270

    authors： Zamò A,Pischimarov J,Schlesner M,Rosenstiel P,Bomben R,Horn H,Grieb T,Nedeva T,López C,Haake A,Richter J,Trümper L,Lawerenz C,Klapper W,Möller P,Hummel M,Lenze D,Szczepanowski M,Flossbach L,Schreder M,Gattei V,O

    更新日期：2018-03-01 00:00:00

  • Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.

    abstract：:Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-a subtype of Hodgkin lymphoma (HL)-is characterized by a low content of tumor cells, the lymphocyte predominant (LP) cells. Transformation into diffuse large B-cell lymphoma (DLBCL) occurs in about 10% of patients. We performed whole-genome mutation analysis of t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2015.328

    authors： Hartmann S,Schuhmacher B,Rausch T,Fuller L,Döring C,Weniger M,Lollies A,Weiser C,Thurner L,Rengstl B,Brunnberg U,Vornanen M,Pfreundschuh M,Benes V,Küppers R,Newrzela S,Hansmann ML

    更新日期：2016-04-01 00:00:00

  • Chloroquine induces basophilic differentiation of HL-60 cells.

    abstract：:Many agents have been known to induce the differentiation of HL-60 cells. However, only a small number of reports on the basophilic differentiation of this cell line are known. In this study we show that the exposure of HL-60 cells to chloroquine induces to differentiate into basophils. This chloroquine-induced change...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Sasaki R,Furukawa Y,Okada K,Nakamura M,Yamane Y,Miura Y,Eguchi M

    更新日期：1997-04-01 00:00:00

  • SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.

    abstract：:The scientific community faces an unexpected and urgent challenge related to the SARS-CoV-2 pandemic and is investigating the role of receptors involved in entry of this virus into cells as well as pathomechanisms leading to a cytokine "storm," which in many cases ends in severe acute respiratory syndrome, fulminant m...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-020-0887-9

    authors： Ratajczak MZ,Kucia M

    更新日期：2020-07-01 00:00:00

  • Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis.

    abstract：:Bone mineral density (BMD) and biochemical markers of bone metabolism were analyzed in 67 adults with ALL (n = 27), AML (n = 14), MDS (n = 6) and CML (n = 20) before and after allogeneic stem cell transplantation (SCT). Median age was 36 years (17-56). Twenty-six out of 53 patients (49%) had osteopenia and osteoporosi...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.leu.2402264

    authors： Massenkeil G,Fiene C,Rosen O,Michael R,Reisinger W,Arnold R

    更新日期：2001-11-01 00:00:00

  • Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

    abstract：:Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2'-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma. CdA was given at a fixed dose (5.6 mg/m2/day) as a 2-h intravenous (i.v.) i...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.leu.2401783

    authors： Van Den Neste E,Louviaux I,Michaux JL,Delannoy A,Michaux L,Sonet A,Bosly A,Doyen C,Mineur P,André M,Straetmans N,Coche E,Venet C,Duprez T,Ferrant A

    更新日期：2000-06-01 00:00:00

  • Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.

    abstract：:Perturbation in iron homeostasis is a hallmark of some hematologic diseases. Abnormal sideroblasts with accumulation of iron in the mitochondria are named ring sideroblasts (RS). RS is a cardinal feature of refractory anemia with RS (RARS) and RARS with marked thrombocytosis (RARS/-T). Mutations in SF3B1, a member of ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.170

    authors： Visconte V,Avishai N,Mahfouz R,Tabarroki A,Cowen J,Sharghi-Moshtaghin R,Hitomi M,Rogers HJ,Hasrouni E,Phillips J,Sekeres MA,Heuer AH,Saunthararajah Y,Barnard J,Tiu RV

    更新日期：2015-01-01 00:00:00

  • Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR.

    abstract：:Molecular cloning of immunoglobulin heavy chain (IGH) translocation breakpoints identifies genes of biological importance in the development of normal and malignant B cells. Long-distance inverse PCR (LDI-PCR) was first applied to amplification of IGH gene translocations targeted to the joining (IGHJ) regions. We repo...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403500

    authors： Sonoki T,Willis TG,Oscier DG,Karran EL,Siebert R,Dyer MJ

    更新日期：2004-12-01 00:00:00

  • Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia.

    abstract：:Donor leukocyte infusions (DLI) have turned out to be an efficient way to re-establish complete remission (CR) in chronic myeloid leukemia (CML) patients relapsing after allogeneic bone marrow transplantation (BMT). In these patients, absence of PCR bcr-abl fusion transcripts confirmed the potency of donor leukocytes ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401144

    authors： Berthou C,Léglise MC,Herry A,Balcon D,Hardy E,Lessard M,Abgrall JF

    更新日期：1998-11-01 00:00:00

  • Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) stu

    abstract：:Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach to JAK2-V617F detection, with assays varying markedly in performance, af...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2013.219

    authors： Jovanovic JV,Ivey A,Vannucchi AM,Lippert E,Oppliger Leibundgut E,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G,Guglielmelli P,van der Reijden BA,Jansen JH,Alpermann T,Schnittger S,Bench A,Tobal K,Wilkins B,Cu

    更新日期：2013-10-01 00:00:00